The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A16 | Other alimentary tract and metabolism products | |
3
|
A16A | Other alimentary tract and metabolism products | |
4
|
A16AX | Various alimentary tract and metabolism products | |
5
|
A16AX16 |
| Active Ingredient |
|---|
|
Givosiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of aminolevulinic acid synthase 1 (ALAS1) messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference, resulting in a reduction of induced liver ALAS1 mRNA towards normal. This leads to reduced circulating levels of neurotoxic intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG), the key causal factors of attacks and other disease manifestations of AHP. |
| Document | Type | Information Source | |
|---|---|---|---|
| GIVLAARI Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| GIVLAARI Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.